ClinicalTrials.gg
CompletedNCT01972724ADDUpdated Sep 12, 2018Results posted

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

A Phase 4 interventional study of Pioglitazone and Metformin in Type II Diabetes Mellitus, sponsored by Takeda. Completed at 9 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-12.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
58th of 122
114 · median 103
Started
2013
with 3 others
Phase 4
57 of 122
4 open now
Registered
87th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment, is one of 4 that started in 2013, is one of 57 in phase 4, and was the 87th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and sulfonylurea.

Read the detailed description

The drug being tested in this study is called pioglitazone. Pioglitazone is being tested to treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus. This study will look at glycemic control in people who take triple oral therapy of metformin, sulfonylurea, and pioglitazone 15 mg.

The study will enroll approximately 114 patients. All participants will be asked to take one pioglitazone tablet at the same time each day throughout the study as well as continuing their previous dose of metformin and sulfonylurea.

This multi-center trial will be conducted in Korea. The overall time to participate in this study is up to 25 weeks. Participants will make 4 visits to the hospital or endocrinologist's office, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Type II Diabetes Mellitus

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants meeting the following criteria will be considered for inclusion in the study:

  1. Institutional Review Board (IRB)-approved written form (ICF) must be obtained from the participant or legally authorized representative prior to any trial related procedure (including withdrawal of prohibited medication, if applicable).
  2. Participants with a history of clinical diagnosis of established type 2 diabetes mellitus defined by the American Diabetes Association (ADA) criteria 2012.
  3. Male or female between 18 and 80 years of age.
  4. Participants with stable triple oral therapy of metformin + sulfonylurea + pioglitazone (ACTOS) 15 mg or ACTOSMET(Pioglitazone 15mg/Metformin 850mg) and sulfonylurea for at least 12 weeks at the screening visit.
  5. Participants with glycosylated () ≥7.0% at the screening visit.
  6. Participants with C-peptide ≥1.0 ng/mL at the screening visit.
  7. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from screening throughout the duration of the study, up to 30 days after the last dose of the study medication.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from enrollment:

  1. Participants with type 1 diabetes mellitus or secondary forms of diabetes.
  2. Participants who have been treated with insulin for ≥7 days within 3 months prior to the screening visit.
  3. Participants with a history of bladder cancer or participants with active bladder cancer.
  4. Participants with a history of acute diabetic complications such as diabetic ketoacidosis.
  5. Participants with a history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
  6. Participants with unstable or rapidly progressive diabetic retinopathy, nephropathy (estimated [eGFR] \<60mL/min/1.73m2).
  7. Participants with cardiac insufficiency (e.g., a myocardial infarction, a coronary angioplasty or bypass graft, unstable angina, , or a documented cerebrovascular accident within 6 months prior to the screening visit).
  8. Participants with cardiac failure or history of cardiac failure ( [NYHA] Stages 3 to 4).
  9. Participants with a serum (ALT) level ≥2.5 times the (ULN), active liver disease, or jaundice.
  10. Participants taking concomitant gemfibrozil or other strong cytochrome P450 (CYP)2C8 inhibitors.
  11. Participants with a history of recurrent or severe hypoglycemia.
  12. Participants with a history of any hemoglobinopathy (such as hemolytic anemias or sickle cell disease) that may affect determination of .
  13. Participants with uninvestigated microscopic hematuria
  14. Participants with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since the study drug contains lactose.
  15. Participants with any other condition judged by the Investigator as unsuitable for the study.
  16. Participants who have used any or experimental drugs or devices within 60 days of the screening visit.
  17. Lactating or pregnant female. A positive pregnancy test before the first administration of investigational medicinal product (IMP) or breastfeeding.
  18. Male participants planning to father during clinical trial conduct or within 3 months after the last planned dose of the IMP.
  19. Participants were previously enrolled into the current clinical trial.
  20. The participants participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic effect of the IMP of that clinical trial cannot be excluded.
  21. Participants are considered unable or unwilling to co-operate adequately, i.e., to follow clinical trial procedures after Investigator has adequately instructed (e.g., language difficulties, etc.) or participants are anticipated not to be available for scheduled clinical trial visits/procedures.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15 mg (Double-Blind)

    Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.

    Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea

  • Experimental
    Pioglitazone 30 mg (Double-Blind)

    Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.

    Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea

  • Experimental
    Pioglitazone 30 mg (Open-Label)

    Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.

    Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose at Week 24

    The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24

07

Results

Posted Jul 24, 2018

Participant flow

Participants took part in the study at 15 investigative sites in Korea from 16 December 2013 to 17 October 2016.

Double-Blind
Participant flow — Double-Blind
MilestonePioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
Started19180
Intent-to-treat:received study drug17170
Completed1090
Not completed990
Withdrew: Rescue criteria met100
Withdrew: Adverse event100
Withdrew: Withdrawal of consent210
Withdrew: Significant protocol deviation580
Open-Label
Participant flow — Open-Label
MilestonePioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
Started0077
Completed0072
Not completed005
Withdrew: Withdrew consent003
Withdrew: Significant protocol deviation002

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
percentage of glycosylated hemoglobinPioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24-0.0003 ± 0.00725-0.0030 ± 0.00894-0.0275 ± 0.21126
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 24

The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose at Week 24
mmol/LPioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
Change From Baseline in Fasting Plasma Glucose at Week 240.6727 ± 1.80662-0.4278 ± 1.88067-0.4412 ± 2.30378

Adverse events

Collected over First dose of study drug up to 30 days after the last dose of study drug (Up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pioglitazone 15 mg (Double-Blind)—1/17 (5.9%)3/17 (17.6%)
Pioglitazone 30 mg (Double-Blind)—0/17 (0%)7/17 (41.2%)
Pioglitazone 30 mg (Open-Label)—3/77 (3.9%)0/77 (0%)
Most frequent serious events
Most frequent serious events
EventPioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/170/170/77
Facial bones fractureInjury, poisoning and procedural complications0/170/171/77
Pneumothorax traumaticInjury, poisoning and procedural complications0/170/171/77
Rib fractureInjury, poisoning and procedural complications0/170/171/77
Musculoskeletal painMusculoskeletal and connective tissue disorders0/170/171/77
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/170/171/77
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)
OedemaGeneral disorders0/172/170/77
Conjunctival haemorrhageEye disorders1/170/170/77
Eyelid oedemaEye disorders0/171/170/77
VomitingGastrointestinal disorders1/170/170/77
FolliculitisInfections and infestations0/171/170/77
Herpes zosterInfections and infestations0/171/170/77
NasopharyngitisInfections and infestations1/170/170/77
OnychomycosisInfections and infestations0/171/170/77
Tinea pedisInfections and infestations0/171/170/77
Ligament injuryInjury, poisoning and procedural complications1/170/170/77

Baseline characteristics

ITT population included participants who took at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Mean59.6 ± 8.7357.0 ± 12.059.2 ± 7.8858.6 (31 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Female973551
Male8104260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Not Hispanic or Latino171777111
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Asian171777111
Region of Enrollment
Region of Enrollment(Participants)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Korea, Republic Of171777111
Height
Height(cm)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Mean161.94 ± 8.392163.50 ± 9.702163.25 ± 9.148162.89 (145.9 to 185.0)
Weight
Weight(kg)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Mean70.39 (48.0 to 97.0)71.20 (47.5 to 100.0)70.38 (46.3 to 101.0)70.65 (46.3 to 101.0)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Pioglitazone 15 mg (Double-Blind)Pioglitazone 30 mg (Double-Blind)Pioglitazone 30 mg (Open-Label)Total
Mean26.86 (22.2 to 36.7)26.46 (20.9 to 30.8)26.25 (19.0 to 34.6)26.52 (19.0 to 36.7)
08

Study locations

9 sites
  • Chagwon, Korea, Republic of
  • Daegu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Gwangju, Korea, Republic of
  • Gyeonggi-do, Korea, Republic of
  • Jeonju, Korea, Republic of
  • Seoul, Korea, Republic of
  • Ulsan, Korea, Republic of
  • Wonju, Korea, Republic of
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Oct 2016, 34 months.

Results were first posted in Jul 2018, 1 year 9 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 34 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Oct 30, 2013
StartActual
Dec 16, 2013
Primary completionActual
Oct 17, 2016
CompletionActual
Oct 17, 2016
Results first posted
Jul 24, 2018
Last update
Sep 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01972724
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 30, 2013
Start date
Dec 16, 2013
Primary completion
Oct 17, 2016
Completion
Oct 17, 2016
Results posted
Jul 24, 2018
Last update
Sep 12, 2018

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Metformin · Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea

Start the discussion